Pfizer Discussing Trovan Labeling With FDA; Hepatic Injuries "Unpredictable"
Executive Summary
The unpredictability of liver injuries associated with use of Trovan (trovafloxacin) is the challenge facing Pfizer and the probable point-of-departure for discussions with FDA.